['hepatitis c']
['sofosbuvir', 'ribavirin', 'grazoprevir/elbasvir (100 mg/50 mg) fdc']

        Inclusion Criteria:

          -  Weigh ≥40 kg and ≤125 kg

          -  documented chronic HCV GT1, GT4, or GT6 infection

          -  cirrhosis/absence of cirrhosis defined by liver biopsy, Fibroscan, or FibroSure®

          -  either treatment naïve or PR Null Responder, PR Partial Responder, or PR Prior
             Relapser

          -  participant and partner both agree to use at least use at least 2 effective methods of
             contraception from at least 2 weeks prior to Day 1 and continue until up to 6 months
             after last dose of study drug, or longer if dictated by local regulations

        Exclusion Criteria:

          -  has evidence of decompensated liver disease

          -  is coinfected with hepatitis B virus (e.g. hepatitis B surface antigen positive) or
             human immunodeficiency virus

          -  history of malignancy ≤5 years prior to signing informed consent, or is under
             evaluation for other active or suspected malignancy

          -  has cirrhosis and liver imaging within 6 months of Day 1 showing evidence of
             hepatocellular carcinoma (HCC) or is under evaluation for HCC

          -  has any of the following conditions: immunologically-mediated disease, organ
             transplants other than cornea and hair, poor venous access that precludes routine
             peripheral blood sampling, history of gastric surgery or malabsorption disorders, or
             any medical condition requiring, or likely to require, chronic systemic administration
             of corticosteroids during the course of the trial, history of chronic hepatitis not
             caused by HCV
      